(People's Daily health client Chen Linhui)
According to incomplete statistics from the People's Daily health client, there were at least 15 investment and financing incidents in the field of medicine and health this week, with a cumulative amount of more than 1 billion yuan, of which the new drug research and development field was the most expensive, with a financing amount of 570 million yuan.
Unino Biotech: Completed a Series A financing of 160 million yuan
On February 10, Unino Biotech announced that it has completed a round of financing of 160 million yuan, led by Matrix Partners Venture Capital, and all angel shareholders such as Kaifeng Venture Capital, Northern Lights Venture Capital, Lichen Investment and Chengdu Tianfu International Bio-City Fund participated in this round of financing. This round of financing will be mainly used to further improve EUSENO's unique universal CAR-T cell technology platform CBT-X20, prepare for the Sino-US IND declaration of the core product AT19, and the construction of the company's scientific research and production facilities.
Founded in Chengdu in December 2020, Usaino Biotech is a start-up biotechnology company focusing on the development and commercialization of general-purpose cell therapy products.
Shimai Pharmaceutical: Completed a new round of C financing of hundreds of millions of yuan
On February 10, Shimai Pharmaceutical announced the completion of a new round of financing of hundreds of millions of yuan, which was led by Taikun Fund, and Haoyue Capital served as the financial advisor for this round of financing. The funds raised will be mainly used to promote domestic and foreign clinical trials of core blockbuster products such as LAG-3 antibody DNV3 (solid tumor and lymphoma), EGFR/CD3 dual anti-SMET12 (EGFR high expression of solid tumor), CMD003 (autoimmune system disease) and so on.
According to public information, Shimai Pharmaceutical was established in September 2017 as an innovative company dedicated to the research and development of antibody drugs for malignant tumors and autoimmune diseases.
ChengTian Technology: Completed the A+ round of financing of 100 million yuan
On February 10, Hangzhou Chengtian Technology announced the completion of a round of financing of 100 million yuan A+. This round of financing is led by Dachen Caizhi, followed by Anxin Securities and Poly Capital, and the old shareholder Lanchi Venture Capital continues to invest, and Potential Capital serves as the exclusive financial adviser for this financing.
According to the company's official website, Hangzhou Chengtian Science and Technology Development Co., Ltd. was established in January 2017 and is committed to the development of exoskeleton robot technology, intelligent medical devices, special robot technology and intelligent systems.
In November 2021, Cheng Tian Technology Won the 2021 China Design Intelligent Manufacturing Award, and exhibited the 2021 World Industrial Conference Excellent Industrial Design Achievements Exhibition at home and abroad. Youfu Robot exhibited the "Elephant Wai Huanzhong" Chinese Design and Intelligent Manufacturing Excellent Works Exhibition. According to the official website of ChengTian Technology.
Rui touch technology: completed nearly 100 million yuan A round of financing
On February 10, Shanghai Ruitou Technology Co., Ltd., a surgical robot company, announced the completion of a round of financing of nearly 100 million yuan, with the investors being Haosheng Jinrui Fund, Qianrong Chuanghe, AUO Venture Capital, and Xilin Investment as the financial advisor for the long-term exclusive and current round of transactions. This round of funds will be used for the NMPA registration of its three major surgical robot products, clinical trials, and the development and brand building of the hospital market.
According to public information, Rui Touch Technology was established in March 2019, focusing on the research and development of precision puncture surgery robots.
Xinyong Technology: Completed tens of millions of yuan angel round financing
On February 10, Xinyong Technology announced the completion of an angel round of financing of tens of millions of yuan, exclusively invested by Fengrui Capital, which is mainly used for algorithm iteration, sensor research and development, product production, and application and registration of class II medical device certificates.
Xinyong Technology is a young company founded in 2020, mainly doing continuous blood pressure monitoring product research and development, public information shows that Xinyong Technology has started the application process for medical device Class II certificate in October 2021, and will conduct type inspection of products in February this year.
Zhongjing Pukang: Completed tens of millions of yuan A round of financing
On February 10, Zhongjing Pukang completed tens of millions of yuan A round of financing, this round was led by Hongrun Venture Capital, Zhongguancun Qihang and Zhongguancun Synergy Fund followed by Investment, Fangyuan Capital/Optimas Capital continued to serve as financial advisors, and the historical shareholders also included Taiyu Investment and Tengye Venture Capital. This round of financing will be mainly used to promote the clinical trial and commercialization of the three types of certificates. Zhongjing Pukang is a metabolomics tumor early screening company.
Youjia Health: Completed the B round of tens of millions of yuan financing
On February 9, Youjia Health announced the completion of the first financing of the B round of tens of millions of yuan, which was exclusively completed by Kangyu Capital, and the financing funds will be used to continue to build the "home medical care core" medical service system of Youjia Health. Founded in June 2017, Youjia Health connects medical, insurance and customers through the Preferred Healthcare Network to provide product innovation, risk control and medical management services to insurance institutions and their customers. Since May 2021, Youjia Health has successively jointly developed "Internet outpatient insurance" with the head insurance company Taikang Online, Ping An Property & Casualty, PICC Property & Casualty, the head Internet insurance platform Weibao, and the head insurance brokerage company Datong.
Huazhuo Technology: Completed a round of financing of 100 million yuan A++
On February 9, Huazhuo Technology recently announced the completion of a round of financing of 100 million yuan A++, which was led by Qiming Venture Capital. Huazhuo Technology is committed to changing the integrated development, implementation services, and user application acquisition mode of traditional medical information systems based on the operating system built by the new technology architecture, with the intention of breaking the development bottleneck of medical information companies under the traditional framework. Huazhuo Technology is the first company to carry out a new top-level design and development reconstruction of traditional medical information system based on cloud-native architecture.
Jinlan Gene: Completed a round of financing of 200 million yuan
On February 8, Beijing Jinlan Gene Technology Co., Ltd. completed a round of financing of 200 million yuan. According to public information, Jinlan Gene focuses on the innovative research and development of gene therapy drugs. This round of financing is jointly led by Joaquin Investment and Yizhuang SDIC's Specialized Special New Fund. This round of financing will continue to invest in the research and development of new drug products for gene therapy. It mainly includes the clinical trials of three self-developed gene drugs that have entered the IND stage, the research and development of newly established gene drugs and the IND registration declaration, the technological innovation and improvement of gene drug delivery technology, and the core capacity building of CMC.
Kaiskaidi: Completed nearly 100 million YUAN Pre-A+ round of financing
On February 8, Kaiskaidi (Shanghai) Pharmaceutical Technology Co., Ltd. announced the completion of nearly 100 million yuan Pre-A+ round of financing. This round of financing is led by the fund of the new investor West Lake Innovation (Hangzhou) Equity Investment Co., Ltd., and the old shareholders such as Gaorong Capital, Fuhui Venture Capital and Gemdale Capital continue to follow suit. Founded in 2017, Kathkaidi features the original and innovative development of drugs that target nuclear receptors and G protein-coupled receptors (GPCRs), focusing on the study of metabolic and inflammatory diseases.
Yimai Medical: Completed tens of millions of yuan A round of financing
On February 8, the medical digital product platform Yimai Medical completed a round of financing of tens of millions of yuan, led by Shangyuan Capital and followed by CITIC Venture Capital. Imai Medical's digital monitoring product platform has developed a continuous auscultation recorder (gastrointestinal function monitoring), breathing/heart sound monitoring system (continuous auscultation of lung diseases, cardiac system diseases), wireless bedside multi-parameter monitoring system (including six conventional bedside monitoring indicators), etc. Based on technologies in the fields of data processing and sensors, combined with the two product platforms, Imai Medical will continue to develop more digital products that meet clinical needs and expand the market space.
Liwen Institute: Completed the 10 million yuan seed round financing
On February 8, Liwen completed a seed round of financing of 10 million yuan, and the investor was Zhen Fund. Liwen Institute is an AI-driven protein design startup. The financing funds were mainly used for the construction of wet and dry laboratories, equipment procurement and team building. Founded in September 2021, Liwen Institute starts from the law of protein co-evolution, focuses on driving and giving proteins a broader design and production and life application scenarios driven by "artificial intelligence algorithm + wet experiment process", which is used to solve challenging and more socially meaningful problems such as environmental protection, food safety, and medical treatment.
Yusen Jianheng: Completed more than 200 million yuan A round of financing
On February 8, Shanghai Yusen Jianheng Biopharma announced the completion of more than 200 million yuan of Series A financing. This round of financing was led by Shenzhen Sharing Investment, followed by Zhangjiang Haoheng and Yingke Capital, and the original shareholders continued to participate in this round of investment. The funds raised will be used to conduct and accelerate domestic and foreign clinical trials of UA007 and UA021, the development of small molecule drugs with multiple new targets, and the development of specific dual antibodies. According to public information, Yusen Jianheng focuses on cancer and autoimmune diseases, targets difficult drug targets and key oncogenic genes, and the research and development pipeline includes small molecule targeted drugs, recombinant proteins and mono/double antibody drugs.
Basis Point Bio: Completed a C++ round of financing with a total amount of 120 million yuan
On February 7, Basis Point Biotech announced the completion of a C++ round of financing totaling 120 million yuan. This round of investment is jointly led by Zhouling Capital and Deyi Capital. Founded in 2015, Basis Point Bio is an intelligent biological deep cryogenic preservation system solution provider. After this round of financing, Basis Point Bio will continue to launch more innovative and disruptive product lines, and strive to lay out overseas markets.
Aima Biologics: Tens of millions of yuan angel round financing
On February 7, Aima Biotech announced the completion of an angel round of financing, with the first phase of financing amounting to tens of millions of yuan, led by CDH Investment VGC Fund. Aima Bio is a company focused on the research and development of small RNA nucleic acid drugs. This round of financing will first be used for the research and development and production of nucleic acid drugs for brain neurological diseases and anti-super bacteria and antiviral infectious diseases.
